I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 6 studies | 33% ± 11% | |
| enterocyte | 5 studies | 36% ± 17% | |
| transit amplifying cell | 5 studies | 31% ± 10% | |
| intestinal crypt stem cell | 4 studies | 34% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 6 studies | 33% ± 11% | |
| enterocyte | 5 studies | 36% ± 17% | |
| transit amplifying cell | 5 studies | 31% ± 10% | |
| intestinal crypt stem cell | 4 studies | 34% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| intestine | 4 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 93% | 965.50 | 211 / 226 | 46% | 27.22 | 185 / 406 |
| intestine | 69% | 9975.75 | 669 / 966 | 56% | 45.80 | 294 / 527 |
| stomach | 46% | 16.24 | 164 / 359 | 38% | 15.88 | 108 / 286 |
| spleen | 78% | 46.87 | 188 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 56% | 19.69 | 183 / 328 | 19% | 4.26 | 34 / 178 |
| lymph node | 0% | 0 | 0 / 0 | 45% | 20.76 | 13 / 29 |
| breast | 21% | 38.90 | 98 / 459 | 17% | 4.40 | 195 / 1118 |
| peripheral blood | 35% | 294.69 | 328 / 929 | 0% | 0 | 0 / 0 |
| bladder | 10% | 1.48 | 2 / 21 | 26% | 12.36 | 129 / 504 |
| lung | 17% | 3.87 | 101 / 578 | 12% | 1.33 | 140 / 1155 |
| ovary | 7% | 1.08 | 13 / 180 | 16% | 4.08 | 70 / 430 |
| esophagus | 8% | 3.50 | 113 / 1445 | 14% | 2.04 | 25 / 183 |
| prostate | 14% | 5.68 | 34 / 245 | 5% | 0.54 | 27 / 502 |
| uterus | 12% | 6.25 | 20 / 170 | 6% | 0.80 | 28 / 459 |
| kidney | 11% | 2.31 | 10 / 89 | 5% | 0.21 | 49 / 901 |
| tonsil | 0% | 0 | 0 / 0 | 16% | 1.21 | 7 / 45 |
| thymus | 7% | 2.85 | 44 / 653 | 3% | 0.22 | 17 / 605 |
| brain | 5% | 1.60 | 142 / 2642 | 1% | 0.07 | 8 / 705 |
| adipose | 3% | 1.00 | 42 / 1204 | 0% | 0 | 0 / 0 |
| skin | 2% | 0.68 | 37 / 1809 | 1% | 0.08 | 6 / 472 |
| adrenal gland | 3% | 0.75 | 8 / 258 | 0% | 0 | 0 / 230 |
| blood vessel | 3% | 0.67 | 37 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 2% | 0.58 | 20 / 803 | 0% | 0 | 0 / 0 |
| heart | 1% | 0.16 | 8 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0008202 | Biological process | steroid metabolic process |
| GO_0052695 | Biological process | cellular glucuronidation |
| GO_0008210 | Biological process | estrogen metabolic process |
| GO_0016020 | Cellular component | membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0015020 | Molecular function | glucuronosyltransferase activity |
| GO_0001972 | Molecular function | retinoic acid binding |
| Gene name | UGT2B17 |
| Protein name | UDP-glucuronosyltransferase (EC 2.4.1.17) UDP-glucuronosyltransferase 2B17 (UDPGT 2B17) (UGT2B17) (EC 2.4.1.17) (C19-steroid-specific UDP-glucuronosyltransferase) (C19-steroid-specific UDPGT) |
| Synonyms | |
| Description | FUNCTION: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile . Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol) . . |
| Accessions | A0A804HJ67 ENST00000317746.3 ENST00000684088.1 O75795 |
